

Laura Evangelista

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5246410/publications.pdf>

Version: 2024-02-01

195
papers

3,259
citations

186254

28
h-index

197805

49
g-index

200
all docs

200
docs citations

200
times ranked

3904
citing authors

#	ARTICLE	IF	CITATIONS
1	Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2013, 38, 305-314.	1.3	255
2	Utility of Choline Positron Emission Tomography/Computed Tomography for Lymph Node Involvement Identification in Intermediate- to High-risk Prostate Cancer: A Systematic Literature Review and Meta-analysis. <i>European Urology</i> , 2013, 63, 1040-1048.	1.9	251
3	New Clinical Indications for 18 F/ 11 C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. <i>European Urology</i> , 2016, 70, 161-175.	1.9	184
4	Small-bowel MRI in children and young adults with Crohn disease: retrospective head-to-head comparison of contrast-enhanced and diffusion-weighted MRI. <i>Pediatric Radiology</i> , 2013, 43, 103-114.	2.0	96
5	PET/MRI in prostate cancer: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 859-873.	6.4	85
6	Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 464-473.	6.4	79
7	FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series. <i>World Journal of Clinical Oncology</i> , 2011, 2, 348.	2.3	75
8	State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation. <i>Clinical and Translational Imaging</i> , 2021, 9, 299-339.	2.1	70
9	Gleason Score at Diagnosis Predicts the Rate of Detection of ¹⁸ F-Choline PET/CT Performed When Biochemical Evidence Indicates Recurrence of Prostate Cancer: Experience with 1,000 Patients. <i>Journal of Nuclear Medicine</i> , 2015, 56, 209-215.	5.0	69
10	18F-FDG PET/CT in non-small-cell lung cancer patients. <i>Nuclear Medicine Communications</i> , 2019, 40, 802-807.	1.1	63
11	Comparison between conventional imaging (abdominal and pelvic computed tomography and bone scan) and [¹⁸ F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- to high-risk prostate cancer: A retrospective analysis. <i>Scandinavian Journal of Urology</i> , 2015, 49, 345-353.	1.0	56
12	Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. <i>Cancer</i> , 2012, 118, 5454-5462.	4.1	55
13	Early bone marrow metastasis detection: The additional value of FDG-PET/CT vs. CT imaging. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 448-453.	5.6	50
14	Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 404-413.	6.4	47
15	Diffusion-weighted MRI for detection and differentiation of musculoskeletal tumorous and tumor-like lesions in pediatric patients. <i>World Journal of Pediatrics</i> , 2012, 8, 342-349.	1.8	46
16	18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis. <i>Current Radiopharmaceuticals</i> , 2016, 9, 244-257.	0.8	46
17	Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 293-301.	6.4	45
18	Comparison between anatomical cross-sectional imaging and 18F-FDG PET/CT in the staging, restaging, treatment response, and long-term surveillance of squamous cell head and neck cancer. <i>Nuclear Medicine Communications</i> , 2014, 35, 123-134.	1.1	44

#	ARTICLE	IF	CITATIONS
19	18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature. <i>Annals of Nuclear Medicine</i> , 2020, 34, 601-619.	2.2	42
20	Myocardial perfusion imaging and risk classification for coronary heart disease in diabetic patients. The IDIS study: a prospective, multicentre trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 387-395.	6.4	38
21	Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1546-1562.	6.4	37
22	[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2022, 5, 273-282.	5.4	37
23	Boron neutron capture therapy and 18F-labelled borophenylalanine positron emission tomography: A critical and clinical overview of the literature. <i>Applied Radiation and Isotopes</i> , 2013, 74, 91-101.	1.5	36
24	Follow-up of patients with early breast cancer: Is it time to rewrite the story?. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 130-141.	4.4	36
25	Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review. <i>Clinical Imaging</i> , 2020, 67, 113-116.	1.5	35
26	18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1348.	3.7	34
27	Usefulness of Stress Cardiac Single-Photon Emission Computed Tomographic Imaging Late After Percutaneous Coronary Intervention for Assessing Cardiac Events and Time to Such Events. <i>American Journal of Cardiology</i> , 2007, 100, 436-441.	1.6	31
28	The role of PET/CT in the evaluation of patients affected by limbic encephalitis: A systematic review of the literature. <i>Journal of Neuroimmunology</i> , 2015, 284, 44-48.	2.3	29
29	Biochemical and Pathophysiological Premises to Positron Emission Tomography With Choline Radiotracers. <i>Journal of Cellular Physiology</i> , 2017, 232, 270-275.	4.1	28
30	Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2020, 10, 598.	2.6	28
31	The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer. <i>Abdominal Imaging</i> , 2015, 40, 3230-3237.	2.0	27
32	Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. <i>Journal of the Turkish German Gynecology Association</i> , 2015, 16, 137-144.	0.6	27
33	Tumor Marker "Guided PET in Breast Cancer Patients" A Recipe for a Perfect Wedding. <i>Clinical Nuclear Medicine</i> , 2012, 37, 467-474.	1.3	26
34	The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review. <i>Annals of Nuclear Medicine</i> , 2021, 35, 767-776.	2.2	26
35	18F-fluoromethylcholine or 18F-fluoroethylcholine pet for prostate cancer imaging: which is better? A literature revision. <i>Nuclear Medicine and Biology</i> , 2015, 42, 340-348.	0.6	25
36	The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer. <i>European Urology Focus</i> , 2020, 6, 146-150.	3.1	25

#	ARTICLE	IF	CITATIONS
37	Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. <i>Abdominal Radiology</i> , 2018, 43, 2391-2399.	2.1	23
38	18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosisâ€”A Multicenter Retrospective Study. <i>Cancers</i> , 2019, 11, 700.	3.7	23
39	Stress cardiac single-photon emission computed tomographic imaging late after coronary artery bypass surgery for risk stratification and estimation of time to cardiac events. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 46-51.	0.8	22
40	New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology. <i>Current Radiopharmaceuticals</i> , 2013, 6, 117-123.	0.8	22
41	Radiolabeled choline PET/CT before salvage lymphadenectomy dissection. <i>Nuclear Medicine Communications</i> , 2016, 37, 1223-1231.	1.1	21
42	PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature. <i>Cancers</i> , 2022, 14, 1770.	3.7	21
43	Impact of inducible ischemia by stress SPECT in cardiac risk assessment in diabetic patients: Rationale and design of a prospective, multicenter trial. <i>Journal of Nuclear Cardiology</i> , 2008, 15, 100-104.	2.1	20
44	Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 85-94.	6.4	20
45	Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 117-124.	4.4	20
46	[18F]FDG PET/MRI in rectal cancer. <i>Annals of Nuclear Medicine</i> , 2021, 35, 281-290.	2.2	20
47	How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals. <i>Nuclear Medicine Communications</i> , 2012, 33, 679-688.	1.1	18
48	Indeterminate Lung Nodules in Cancer Patients: Pretest Probability of Malignancy and the Role of ¹⁸ F-FDG PET/CT. <i>American Journal of Roentgenology</i> , 2014, 202, 507-514.	2.2	18
49	Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 74-79.	4.4	18
50	The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study. <i>Cancers</i> , 2019, 11, 1831.	3.7	18
51	Molecular Imaging of Pulmonary Inflammation and Infection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 894.	4.1	18
52	Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid. <i>Annals of Nuclear Medicine</i> , 2018, 32, 7-15.	2.2	17
53	Translational molecular imaging in exocrine pancreatic cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2442-2455.	6.4	17
54	Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1898-1907.	6.4	17

#	ARTICLE	IF	CITATIONS
55	PET/CT and the Response to Immunotherapy in Lung Cancer. <i>Current Radiopharmaceuticals</i> , 2020, 13, 177-184.	0.8	17
56	Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1648-1655.	6.4	16
57	Conflicting or complementary role of computed tomography (<scp>CT</scp>) and positron emission tomography (<scp>PET</scp>)/<scp>CT</scp> in the assessment of thymic cancer and thymoma: our experience and literature review. <i>Thoracic Cancer</i> , 2015, 6, 433-442.	1.9	16
58	Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. <i>Cancer Management and Research</i> , 2017, Volume 9, 789-800.	1.9	16
59	Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art. <i>World Journal of Radiology</i> , 2016, 8, 829.	1.1	16
60	Additional Value of PET Radiomic Features for the Initial Staging of Prostate Cancer: A Systematic Review from the Literature. <i>Cancers</i> , 2021, 13, 6026.	3.7	16
61	Indeterminate pulmonary nodules on CT images in breast cancer patient: The additional value of 18Fâ€FDG PET/CT. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 417-424.	1.8	15
62	Molecular imaging: the emerging role of optical imaging in nuclear medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2150-2153.	6.4	15
63	Is Radiocholine PET/CT Already Clinically Useful in Patients with Prostate Cancer?. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1401-1403.	5.0	15
64	Italian Multicenter Study on Accuracy of 18 F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e267-e273.	0.4	15
65	Positron emission tomography/computed tomography and esophageal cancer in the clinical practice: How does it affect the prognosis?. <i>Journal of Cancer Research and Therapeutics</i> , 2012, 8, 619.	0.9	14
66	Molecular pathways and molecular imaging in breast cancer: An update. <i>Nuclear Medicine and Biology</i> , 2013, 40, 581-591.	0.6	14
67	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e187-e194.	1.9	14
68	Relation between wall thickening on gated perfusion SPECT and functional recovery after coronary revascularization in patients with previous myocardial infarction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1599-1605.	6.4	13
69	Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT? Results from small population with previous breast cancer. <i>Annals of Nuclear Medicine</i> , 2011, 25, 469-477.	2.2	13
70	Preliminary monocentric results of biological characteristics of pregnancy associated breast cancer. <i>Breast</i> , 2014, 23, 19-25.	2.2	13
71	PET/MR in recurrent glioblastoma patients treated with regorafenib: [¹⁸ F]FET and DWI-ADC for response assessment and survival prediction. <i>British Journal of Radiology</i> , 2022, 95, 20211018.	2.2	13
72	Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients. <i>Nuclear Medicine Communications</i> , 2017, 38, 537-545.	1.1	12

#	ARTICLE	IF	CITATIONS
73	Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1908-1914.	6.4	12
74	Microdosimetric measurements in the thermal neutron irradiation facility of LENA reactor. <i>Applied Radiation and Isotopes</i> , 2014, 88, 147-152.	1.5	11
75	Clinical results and economic considerations of 68 Ga-PSMA and radiolabeled choline in prostate cancer. <i>Nuclear Medicine and Biology</i> , 2017, 50, 47-49.	0.6	11
76	Ground glass pulmonary nodules: their significance in oncology patients and the role of computer tomography and 18F-fluorodeoxyglucose positron emission tomography. <i>European Journal of Hybrid Imaging</i> , 2018, 2, 2.	1.5	11
77	Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2871-2882.	6.4	11
78	Incremental prognostic value of cardiac single-photon emission computed tomography after nitrate administration in patients with ischemic left ventricular dysfunction. <i>Journal of Nuclear Cardiology</i> , 2009, 16, 38-44.	2.1	10
79	PET/CT imaging in gynecologic malignancies: A critical overview of its clinical impact and our retrospective single center analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 84-98.	4.4	10
80	18F-FDG PET/MRI in adult sarcomas. <i>Clinical and Translational Imaging</i> , 2020, 8, 405-412.	2.1	10
81	Women in nuclear medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2678-2679.	6.4	10
82	The future of choline PET in the era of prostate specific membrane antigen. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 19-28.	0.7	10
83	FDG PET/CT Volume-Based Quantitative Data and Survival Analysis in Breast Cancer Patients: A Systematic Review of the Literature. <i>Current Medical Imaging</i> , 2023, 19, .	0.8	10
84	Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: a systematic review and meta-analysis. <i>Clinical and Translational Imaging</i> , 2013, 1, 99-109.	2.1	9
85	Use of a portable gamma camera for guiding surgical treatment in locally advanced breast cancer in a post-neoadjuvant therapy setting. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 331-340.	2.5	9
86	Risk stratification and prognostic assessment by myocardial perfusion-gated SPECT in patients with left bundle-branch block and low-intermediate cardiac risk. <i>Annals of Nuclear Medicine</i> , 2012, 26, 559-570.	2.2	8
87	The new era of cancer immunotherapy: what can molecular imaging do to help?. <i>Clinical and Translational Imaging</i> , 2017, 5, 299-301.	2.1	8
88	Immunotherapy and 18F-FDG PET/CT: standardised procedures are needed. <i>Clinical and Translational Imaging</i> , 2019, 7, 313-315.	2.1	8
89	Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma. <i>Nuclear Medicine Communications</i> , 2019, 40, 808-814.	1.1	8
90	Comparison Between 18F-Dopa and 18F-Fet PET/CT in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and Our Experience. <i>Current Radiopharmaceuticals</i> , 2019, 12, 220-228.	0.8	8

#	ARTICLE	IF	CITATIONS
91	Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer. <i>Nuclear Medicine Communications</i> , 2022, 43, 212-219.	1.1	8
92	Comparison of 18F-FDG positron emission tomography/computed tomography and computed tomography in patients with already-treated breast cancer: diagnostic and prognostic implications. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 56, 375-84.	0.7	8
93	Therapeutic impact of 18F-FDG PET/CT in recurrent differentiated thyroid carcinoma. <i>Radiologia Medica</i> , 2014, 119, 97-102.	7.7	7
94	Radiolabelled choline and FDG PET/CT: two alternatives for the assessment of lymph node metastases in patients with upper urinary tract urothelial carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 576-577.	6.4	7
95	Diagnostic value of contrast-enhanced CT combined with 18-FDG PET in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>Abdominal Radiology</i> , 2018, 43, 1094-1100.	2.1	7
96	Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary. <i>Frontiers in Oncology</i> , 2018, 8, 581.	2.8	7
97	Clinical Impact of 18F-FDG PET/CT in the Diagnostic Workup of Pancreatic Ductal Adenocarcinoma: A Systematic Review. <i>Diagnostics</i> , 2020, 10, 1042.	2.6	7
98	The effects of androgen deprivation therapy on the 18F-Choline uptake in prostate cancer patients undergoing neoadjuvant treatment. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 278-283.	0.7	7
99	Reclassification of cardiovascular risk by myocardial perfusion imaging in diabetic patients with abnormal resting electrocardiogram. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 588-593.	2.6	6
100	Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from 223Ra-dichloride to new horizons for therapeutic response assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 5-7.	6.4	6
101	Alternative imaging strategy of solitary pulmonary nodule by FDG PET/CT. <i>European Journal of Radiology</i> , 2017, 90, 188-191.	2.6	6
102	18F-Choline PET/CT in Leptomeningeal Breast Cancer Metastases. <i>Clinical Nuclear Medicine</i> , 2019, 44, e96-e97.	1.3	6
103	The prediction of response to immunotherapy in non-small cell lung cancer patients by 18F-FDG PET/CT. <i>Journal of Thoracic Disease</i> , 2019, 11, E221-E223.	1.4	6
104	10-Year Clinical Experience With 18F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2020, 45, 594-603.	1.3	6
105	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1522-1537.	6.4	6
106	Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results From a Bicentric Population. <i>Current Radiopharmaceuticals</i> , 2016, 9, 169-177.	0.8	6
107	Copper, PET/CT and prostate cancer: a systematic review of the literature. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 382-392.	0.7	6
108	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	3.7	6

#	ARTICLE	IF	CITATIONS
109	Diagnostic and prognostic value of gated myocardial perfusion single-photon emission computed tomography in low-risk patients with left bundle-branch block. <i>Nuclear Medicine Communications</i> , 2012, 33, 491-497.	1.1	5
110	18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients. <i>Nuclear Medicine Communications</i> , 2014, 35, 160-168.	1.1	5
111	Multicentric study on 18F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2015, 34, 24-29.	0.0	5
112	A Solitary Metastasis for a Malignant Schwannoma in the Gallbladder Detected by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, 666-667.	1.3	5
113	Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5â€%ng/ml. <i>Nuclear Medicine Communications</i> , 2018, 39, 260-267.	1.1	5
114	Head-to-head comparison between 18F-FDG PET/CT and PET/MRI in breast cancer. <i>Clinical and Translational Imaging</i> , 2019, 7, 99-104.	2.1	5
115	Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer. <i>Abdominal Radiology</i> , 2021, 46, 4401-4409.	2.1	5
116	Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 205-215.	0.7	5
117	Gender issues in the nuclear medicine community: results from a survey promoted by the EANM Women Empowerment Task Force. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2106-2112.	6.4	5
118	Cardiac performance during exercise in hypertensive patients without ventricular hypertrophy. <i>European Journal of Clinical Investigation</i> , 2009, 39, 664-670.	3.4	4
119	C-reactive protein levels are associated with paraoxonase polymorphism L55M in patients undergoing cardiac SPECT imaging. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 179-184.	1.2	4
120	Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 446-449.	6.4	4
121	Nuclear Imaging and Early Breast Cancer Detection. <i>Current Radiopharmaceuticals</i> , 2014, 7, 29-35.	0.8	4
122	Can 68Ga-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1407-1409.	6.4	4
123	18F-FDG or 68Ga/18F-PSMA PET/CT in recurrent renal cancer?. <i>Clinical and Translational Imaging</i> , 2018, 6, 329-330.	2.1	4
124	Re: Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?. <i>Clinical Nuclear Medicine</i> , 2018, 43, 867-868.	1.3	4
125	Pleural Mesothelioma Detects by 18F-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, e116-e117.	1.3	4
126	Detection rate of 18F-Choline positron emission tomography/computed tomography in patients with non-metastatic hormone sensitive and castrate resistant prostate cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , .	0.7	4

#	ARTICLE	IF	CITATIONS
127	18F-FDG PET/MRI in endometrial cancer: systematic review and meta-analysis. <i>Clinical and Translational Imaging</i> , 0, , 1.	2.1	4
128	Cardiovascular risk stratification of diabetic patients. <i>Minerva Endocrinologica</i> , 2009, 34, 205-21.	1.8	4
129	Radiomic features as biomarkers of soft tissue paediatric sarcomas: preliminary results of a PET/MR study. <i>Radiology and Oncology</i> , 2022, 56, 138-141.	1.7	4
130	Single-Photon Emission Computed Tomography After Nitrate Administration Predicts Cardiac Events in Patients With Previous Myocardial Infarction and Left Ventricular Dysfunction. <i>Journal of Cardiac Failure</i> , 2007, 13, 765-768.	1.7	3
131	Prognostic value of myocardial perfusion scintigraphy in elderly patients with hypertension: a 10-year follow-up analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1570-1580.	6.4	3
132	Correlation between Cancer Antigen 15.3 Value and Qualitative and Semiquantitative Parameters of Positron Emission Tomography/Computed Tomography in Breast Cancer Patients. <i>Current Radiopharmaceuticals</i> , 2014, 7, 20-28.	0.8	3
133	Prostate-specific antigen and radiolabelled choline PET/CT for the assessment of response to therapy: synergy or conflicting?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 200-201.	6.4	3
134	Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer. <i>Clinical Imaging</i> , 2017, 43, 110-116.	1.5	3
135	¿Constituir en el futuro los radioligandos de 68 Ga-PSMA la única elección de la Medicina Nuclear para el cáncer de próstata? Actualización clínica. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 103-109.	0.0	3
136	The role of PET/CT in the evaluation of patients with urothelial cancer: a systematic review and meta-analysis. <i>Clinical and Translational Imaging</i> , 2018, 6, 77-89.	2.1	3
137	Italian Tailored Assessment of Lung Indeterminate Accidental Nodule by Proposing a Segmental Pet/Computed Tomography (S-Pet/Ct): Rationale And Study Design of a Retrospective, Multicenter Trial. <i>Current Radiopharmaceuticals</i> , 2018, 11, 46-49.	0.8	3
138	Management of hyperglycemia in oncological patients scheduled for an FDG-PET/CT examination. <i>Clinical and Translational Imaging</i> , 2019, 7, 447-450.	2.1	3
139	The Multicenter Italian Trial Assesses the Performance of FDG-PET /CT Related to Pre-Test Cancer Risk in Patients with Solitary Pulmonary Nodules and Introduces a Segmental Thoracic Diagnostic Strategy. <i>Current Radiopharmaceuticals</i> , 2020, 13, 243-248.	0.8	3
140	The role of 18F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic review. <i>Nuclear Medicine Communications</i> , 2021, 42, 839-845.	1.1	3
141	68Ga-dotatoc vs. 18F-FDG vs. radiolabelled PSMA PET/CT in renal cancer patients. <i>Annals of Translational Medicine</i> , 2019, 7, S150-S150.	1.7	3
142	¹⁸ F-DOPA and ¹⁸ F-FDG PET/CT, Scintigraphic Localization and Radioguided Surgery of Recurrent Medullary Thyroid Cancer: Two Case Reports. <i>Current Radiopharmaceuticals</i> , 2014, 7, 133-137.	0.8	3
143	Association between semiquantitative PET parameters and molecular subtypes of breast invasive ductal carcinoma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 101-111.	0.7	3
144	Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid. <i>Anti-Cancer Drugs</i> , 2015, 26, 232-235.	1.4	2

#	ARTICLE	IF	CITATIONS
145	Discordance rate between radiolabelled choline PET/CT and bone scintigraphy in detecting bone metastases in patients with prostate cancer: a meta-analysis. <i>Clinical and Translational Imaging</i> , 2015, 3, 133-140.	2.1	2
146	Reply to Egesta Lopci, Arturo Chiti, and Massimo Lazzeri's Letter to the Editor re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. <i>Eur Urol</i> 2016;70:161-75. <i>European Urology</i> , 2016, 70, e114-e115.	1.9	2
147	Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomized, Multicenter Study. <i>Lancet</i> 2020;395:1208-16. <i>European Urology Oncology</i> , 2020, 3, 713.	5.4	2
148	Molecular imaging and immunotherapy. <i>International Journal of Biological Markers</i> , 2020, 35, 37-41.	1.8	2
149	Gender balance in the editorial board of nuclear medicine journals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3749-3750.	6.4	2
150	Value of 18F-fluorocholine PET/CT in predicting response to radical radiotherapy in patients with localized prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 71-77.	1.7	2
151	An Incidental Uptake of 18F-Choline at PET/CT in Gastric Neuroendocrine Tumor. <i>Clinical Nuclear Medicine</i> , 2021, 46, e238-e239.	1.3	2
152	Theranostics applications and challenges. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, 297-298.	0.7	2
153	FDG-PET/CT visualises a case of primary hyperparathyroidism in patient with GIST. <i>Minerva Endocrinologica</i> , 2010, 35, 193-5.	1.8	2
154	Colorectal cancer. <i>Nuclear Medicine Communications</i> , 2012, 33, 780-782.	1.1	1
155	Re. <i>Clinical Nuclear Medicine</i> , 2016, 41, 746.	1.3	1
156	The War Is Opened: PSMA vs. 64CuCl2 vs. Choline PET/CT. <i>Journal of Nuclear Medicine</i> , 2019, 60, 292.1-292.	5.0	1
157	Targeting prostate cancer with the anti-PSMA scFvD2B: a theranostic promise for nuclear medicine. <i>Clinical and Translational Imaging</i> , 2019, 7, 295-301.	2.1	1
158	64CuCl2 PET/CT in a Hyperfunctioning Parathyroid Gland. <i>Clinical Nuclear Medicine</i> , 2019, 44, e449-e452.	1.3	1
159	What Is the Role of Imaging in Cancers?. <i>Cancers</i> , 2020, 12, 1494.	3.7	1
160	PET and SPECT Imaging in the SARS-CoV-2 Pandemic. <i>Current Radiopharmaceuticals</i> , 2020, 13, 87-88.	0.8	1
161	PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1709-1711.	6.4	1
162	Should FDG PET/CT or PET/MR replace WBC scan in infectious and inflammatory disease?. <i>Clinical and Translational Imaging</i> , 0, , 1.	2.1	1

#	ARTICLE	IF	CITATIONS
163	MP77-09 EARLY AND LATE IMAGES OF 18F-CHOLINE (FCH) PET/CT FOR THE DETECTION OF PROSTATIC FOSSAE RECURRENCES IN PROSTATE CANCER WITH A BIOCHEMICAL FAILURE (PSA> 2 NG/ML). Journal of Urology, 2018, 199, .	0.4	1
164	PET/MR for evaluation of musculoskeletal malignancies. Clinical and Translational Imaging, 2022, 10, 71-83.	2.1	1
165	Challenges in theragnostics. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 65, .	0.7	1
166	Radionuclide Imaging in Patients with Ischemic Heart Failure. Current Medical Imaging, 2005, 1, 17-23.	0.8	0
167	What are the Best Ways to Reduce the False-positive Rate of 18F-FDG PET/CT in Patients with Breast Cancer?. Nuclear Medicine and Molecular Imaging, 2011, 45, 85-86.	1.0	0
168	FDG Avidity at PET/CT During Adjuvant Hormonal Therapy in Patients With Breast Cancer. Clinical Nuclear Medicine, 2014, 39, e135-e141.	1.3	0
169	MRI and 18F-FDG PET/CT in monitoring the response to neoadjuvant chemotherapy: is it necessary to appropriately select the patients?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1511-1514.	6.4	0
170	Mismatch between perfusion and metabolism in locally advanced breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 803-804.	6.4	0
171	Editorial Comment. Journal of Urology, 2016, 195, 1442-1443.	0.4	0
172	Pitfalls and artifacts of FDG PET/CT in recurrent breast cancer patients. Clinical and Translational Imaging, 2017, 5, 169-182.	2.1	0
173	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2017, , 883-923.		0
174	Re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68 Ga ⁶⁸ Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926-937. European Urology, 2017, 71, e64-e65.	1.9	0
175	Editorial Comment. Journal of Urology, 2018, 199, 733-733.	0.4	0
176	Will 68 Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 103-109.	0.2	0
177	Prostate cancer imaging: when the game gets tough, the hard one gets done!. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2032-2034.	6.4	0
178	Targeted Therapy with Radium-223 of Bone Metastases. , 2018, , 365-377.		0
179	Ectopic Salivary Gland in a Patient With Prostate Cancer at 18F-Choline PET/CT. Clinical Nuclear Medicine, 2018, 43, 593-594.	1.3	0
180	We will continue to grow up together!. Clinical and Translational Imaging, 2020, 8, 231-231.	2.1	0

#	ARTICLE	IF	CITATIONS
181	Role of Sentinel Lymph Node Biopsy in Patients with Locally Advanced Breast Cancer, after Neoadjuvant Chemotherapy. <i>European Journal of Surgical Oncology</i> , 2020, 46, e46.	1.0	0
182	Re: A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT. <i>Clinical Nuclear Medicine</i> , 2020, 45, e219-e220.	1.3	0
183	Skeletal Muscle Metastases in HCC Revealed by 18F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, e592-e593.	1.3	0
184	Re: Hendrik Van Poppel, René Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>Eur Urol</i> 2021;79:327-39. <i>European Urology</i> , 2021, 80, e24-e27.	1.9	0
185	An Incidental Pancreatic Finding at 18F-Choline PET/CT: Chronic Mass-Forming Pancreatitis. <i>Diagnostics</i> , 2021, 11, 1490.	2.6	0
186	Nuclear Imaging and Early Breast Cancer Detection. <i>Journal of Cancer Science & Therapy</i> , 2012, 01, .	1.7	0
187	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2016, , 1-41.		0
188	Imaging of Glycolysis with 18F-FDG PET. , 2017, , 87-94.		0
189	Approaches for Assessment of Response of Bone Metastases to Therapies. , 2017, , 223-249.		0
190	The Bone Pathway: 223Ra-Dichloride. , 2020, , 179-192.		0
191	The Imaging of Lung Cancer: A Complete Vision. <i>Current Radiopharmaceuticals</i> , 2020, 13, 165-165.	0.8	0
192	Nuclear medicine and positron emission tomography imaging in cardiology. <i>Nuclear Medicine Review</i> , 2003, 6, 59-63.	0.5	0
193	The future of imaging for breast cancer recurrence. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 57, 381-2.	0.7	0
194	Prostate cancer imaging and therapy. , 2018, , .		0
195	An incidental finding behind adrenal incidentaloma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2022, 2022, .	0.5	0